EULAR 2025 – Targeting NLRP3 Inflammasome Activation and Inflammation in Gout with NEK7 Molecular Glue Degraders: A Novel Therapeutic Strategy

Monte Rosa Therapeutics Inc. published this content on June 16, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 16, 2025 at 11:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]